Substance and claimed effects

Tinnitus is the conscious perception of sound — most commonly a high-frequency ringing, hissing, or buzzing — in the absence of an external acoustic source. Pooled global adult prevalence of any tinnitus is 14.4% (range 4.1–37.2% across 83 studies); severe tinnitus runs at 2.3% in adults Jarach et al. 2022. Roughly 1–3% of adults report tinnitus that is debilitating Fuller et al. 2020. This entry covers chronic subjective tinnitus — defined as duration ≥6 months and not driven by a treatable identifiable structural cause (pulsatile vascular tinnitus, acoustic neuroma, otosclerosis, impacted cerumen, somatosensory triggers, ototoxic drug effects are all out of scope here and warrant ENT workup). The substance is the chronic condition plus its management programme. Meaningful consequences scored holistically: distress and mood (anxiety/depression comorbidity is large), sleep (insomnia is the single most common secondary complaint), focus (executive-attention impairment is replicated), short-term wellbeing (treated patients report quality-of-life recovery within months), and longevity (indirect via suicide risk and downstream depression — small but real). Beauty dimensions are zero. The intervention bundle is non-pharmacological: cognitive behavioural therapy (CBT), sound therapy, hearing aids if hearing loss is present, mindfulness-based variants (MBCT, ACT), and — newly FDA-approved (2023) — bimodal neuromodulation (Lenire) Conlon et al. 2020.

Evidence by addressing question

mechanism

Tinnitus is a brain phenomenon, not an ear phenomenon in the chronic state. Initiating insult is usually peripheral — noise-induced cochlear hair-cell damage, age-related (presbycusis) high-frequency hearing loss, or ototoxic drug exposure (cisplatin, aminoglycosides, high-dose loop diuretics, salicylates). The cochlear lesion reduces afferent input at the damaged frequency range; central auditory neurons compensate via increased spontaneous firing rates, increased neural synchrony, and tonotopic-map reorganisation in primary auditory cortex (the "central gain" model). The phantom percept emerges as a learned read-out of this disinhibited central activity.

Jastreboff's neurophysiological model — the foundation of tinnitus retraining therapy — adds that distress from tinnitus is generated separately, by limbic (amygdala, anterior cingulate) and autonomic (sympathetic activation, HPA axis) networks recruited via conditioned reflex arcs Jastreboff 1990. The auditory percept and the affective reaction are dissociable. fMRI/MEG/EEG studies show separable cortical networks for tinnitus loudness (auditory cortex) and tinnitus distress (insula, anterior cingulate, prefrontal cortex). This mechanistic separation is the entire basis of habituation-based therapy: the loudness signal cannot be silenced, but the brain's reaction to it can be retrained.

Empirically, psychoacoustic loudness measures (loudness match, pure-tone matching) correlate only weakly with tinnitus-related distress (Tinnitus Handicap Inventory scores) — r ≈ 0.2–0.4 across multiple cohorts of 4000+ patients Henry & Meikle 2000. Self-rated loudness on a numeric scale correlates moderately, because patients with more distress also rate the same physical signal as louder. The clinical inference: lowering perceived intrusion does not require lowering the signal.

evidence

CBT is the most robustly evidenced intervention. The 2020 Cochrane review of 28 RCTs (n=2,733) found CBT produces a clinically significant improvement in tinnitus-related quality of life at end of treatment vs no intervention or tinnitus retraining therapy; low-to-moderate certainty evidence vs audiological care or other active controls (relaxation, information, internet forums). Mode of delivery (face-to-face, internet-based, bibliotherapy) did not differ Fuller et al. 2020. CBT also produces small reductions in comorbid depression. Adverse events are rare. The AAO-HNS 2014 guideline graded the underlying evidence as Grade A (multiple systematic reviews of RCTs) and made CBT a strong recommendation for persistent bothersome tinnitus Tunkel et al. 2014. The 2019 European multidisciplinary guideline reached the same conclusion Cima et al. 2019.

Sound therapy and hearing aids. The 2018 Cochrane review of 8 RCTs (n=590) found hearing aids and sound generators may modestly reduce tinnitus severity, but no included study compared the devices against waiting-list or sham — confidence is low and superiority over placebo is unestablished Sereda et al. 2018. The guidelines treat sound therapy as an option (AAO-HNS Grade B, equilibrium of benefit/harm) Tunkel et al. 2014, and hearing aids as a recommendation when documented hearing loss accompanies tinnitus.

MBCT and ACT. McKenna et al. 2017 (n=75) found MBCT-t superior to relaxation training on tinnitus severity, catastrophising, and acceptance McKenna et al. 2017. Hesser et al. 2012 found internet-delivered ACT and CBT equivalent for tinnitus distress Hesser et al. 2012. Westin et al. 2011 (n=64) found ACT superior to tinnitus retraining therapy at 6-month follow-up Westin et al. 2011.

Bimodal neuromodulation (Lenire). TENT-A1 (Conlon et al. 2020, n=326) reported that combined sound + tongue electrical stimulation produced clinically significant reductions in Tinnitus Handicap Inventory and Tinnitus Functional Index scores in ~80% of compliant participants, sustained at 12 months Conlon et al. 2020. TENT-A2 (2022) and TENT-A3 (2024, used for FDA De Novo approval March 2023) replicated. The trials lack a sham-controlled arm in TENT-A1/A2; TENT-A3 is a within-subject sound-only vs bimodal comparison. Confidence is moderate, response heterogeneous.

Pharmacology. No drug is FDA-approved for tinnitus. The AAO-HNS guideline recommends against routine antidepressants, anxiolytics, and anticonvulsants — RCTs are negative or null Tunkel et al. 2014. Antidepressants help if the patient has comorbid major depression (treating the depression eases tinnitus impact); they do not treat the tinnitus itself.

protocol

Standard care path:

• Audiologic workup first. Pure-tone and speech audiometry to characterise hearing loss; tympanometry; otoscopy. Red-flag screen: unilateral, pulsatile, or sudden tinnitus warrants imaging (MRI with contrast for retrocochlear lesion) per AAO-HNS Tunkel et al. 2014.
• Hearing aid fitting if hearing loss is documented. First-line in CimaEtAl2019 and TunkelEtAl2014 because amplification reduces relative contrast of tinnitus signal against environmental sound; some patients report substantial relief from amplification alone.
• CBT-t programme: 6–12 weekly sessions (typical structure is 8 sessions × 1–2 hours) with a trained psychologist or audiologist. Components: psychoeducation about the central-gain model, cognitive restructuring of catastrophic thoughts ("this will drive me insane"), behavioural experiments (attention re-direction, anxiety exposure), sleep hygiene. Group, individual, internet-delivered (iCBT-t), and bibliotherapy formats are all evidenced Fuller et al. 2020.
• Sound therapy as adjunct: low-level broadband noise, fan, nature sound, or notched/tailor-made music at a level below the tinnitus (mixing point) — never masking. Used during quiet periods, particularly sleep onset.
• Bimodal device (Lenire) for refractory bothersome tinnitus: two 30-minute home sessions/day for ~12 weeks, prescribed by an audiologist; ~€2,500–4,500 cost in 2024–25.

Realistic timeline: meaningful distress reduction within 6–12 weeks of CBT; full habituation (perception fading from conscious foreground) typically 9–18 months.

contraindications

The non-pharmacological treatments are extremely low-risk; adverse events are rare in CBT trials Fuller et al. 2020. Caveats:

• Sudden onset tinnitus (<72 hours), unilateral, or pulsatile — urgent ENT referral; possibly sudden sensorineural hearing loss (steroid window 1–2 weeks), retrocochlear lesion, or vascular pathology.
• Hyperacusis (sound intolerance) commonly coexists with tinnitus; sound therapy needs careful titration to avoid worsening.
• Severe comorbid depression with suicidality — psychiatric stabilisation precedes CBT-t. Tinnitus is associated with elevated suicidal ideation in severe cases.
• Benzodiazepines and gabapentinoids are widely prescribed off-label but high-dose benzodiazepine use may impair the neuroplastic habituation process and creates dependence; AAO-HNS advises against routine use.

misconceptions

• "Nothing can be done about tinnitus." The most damaging belief, perpetuated by clinicians who tell patients to "learn to live with it" without offering a structured habituation programme. Evidence-based treatment exists and works for distress, sleep, and concentration outcomes Fuller et al. 2020 Cima et al. 2019.
• "Treatment must reduce the loudness." Treatment reduces intrusion; the signal often does not change. Loudness and distress are partially independent at the level of brain networks Henry & Meikle 2000.
• "Silence/masking will give relief." Total silence (anechoic chambers, very quiet bedrooms) typically increases tinnitus salience because the relative signal-to-environment ratio rises. Sound enrichment, not silence, is the prescription.
• "Tinnitus comes from the ear." The initiating injury is in the ear; the chronic percept is generated by central auditory and limbic networks. This is why ear-targeted treatments (drops, masking, surgery) generally fail.
• "Supplements (Lipo-Flavonoid, ginkgo, melatonin, zinc) treat tinnitus." The AAO-HNS strongly recommends against ginkgo biloba, melatonin, zinc, and other dietary supplements for routine tinnitus — RCTs are negative Tunkel et al. 2014.

stakes

Untreated chronic bothersome tinnitus carries a substantial psychiatric and functional burden:

• Sleep: Insomnia prevalence in tinnitus cohorts ranges 10–80% depending on assessment criteria, with most studies above 40%; in DSM-IV-TR diagnostic studies, 60% of tinnitus patients meet criteria for insomnia secondary to a general medical condition Asnis et al. 2018. Sleep latency is prolonged; multiple awakenings are common because the percept becomes salient in quiet periods.
• Anxiety: 45% lifetime prevalence of anxiety disorders in tinnitus patients Pattyn et al. 2016. The relationship appears bidirectional — tinnitus worsens anxiety; anxiety amplifies tinnitus salience.
• Depression: 33% co-occurrence in systematic reviews; severe-tinnitus cohorts run higher (60–78% in some series). Logistic regression in population-based cohorts gives OR ≈ 2.0 for depression and ≈ 1.8 for anxiety in tinnitus patients vs controls.
• Cognition: Replicated impairment of executive attention (inhibition, attention-switching) and mixed evidence for working-memory deficits; subjective concentration complaints exceed objective deficits Mohamad et al. 2016. Mechanism: the salient phantom signal competes for top-down cognitive-control resources.
• Quality of life and work: ~750,000 UK GP consultations/year list tinnitus as primary complaint Sereda et al. 2018; tinnitus is the leading service-connected disability among US military veterans.

payoff

Habituation outcomes from controlled trials and clinical series:

• Distress: CBT produces a clinically significant improvement in tinnitus-related quality of life at 3–22 weeks Fuller et al. 2020; effect persists at the limited follow-up windows available.
• Sleep: Treatment of tinnitus distress via CBT secondarily improves sleep onset and maintenance Fuller et al. 2020; sound enrichment at sleep onset is the most consistent felt change patients report.
• Concentration: Reduction in attentional pull toward the percept as habituation progresses; objective executive-attention measures improve in parallel with distress measures.
• Perceived loudness: Often unchanged on psychoacoustic measures even when distress scores fall — but self-rated loudness frequently decreases because affective amplification has reduced.
• Timeline: Onset of distress relief within ~6 weeks of CBT-t; perception fades from conscious foreground over 9–18 months of habituation work (TRT timeline). Bimodal devices report similar 12-week clinical timelines with response sustained at 12 months in TENT-A series.

practicalities

• Access to CBT-t. The major real-world friction. Trained tinnitus-specific CBT clinicians are sparse outside specialist tinnitus centres in the UK, Netherlands, Germany, and a few US academic centres. Internet-delivered CBT (iCBT-t) has equivalent evidence and bridges this gap Fuller et al. 2020; programmes exist via tinnitus-charity portals and some health systems.
• Cost. Audiologic workup: typically covered by insurance / national health systems. CBT-t: 8 sessions × $100–250 in private US practice (~$1,000–2,000); often covered in UK NHS, Dutch, German, Australian/NZ public systems. Hearing aids: $1,500–6,000/pair in US (insurance variable); largely covered in UK NHS and many EU systems. Bimodal (Lenire): €2,500–4,500 plus ~€100–200/month device-rental in some models. App-based / bibliotherapy CBT: $50–300 one-time.
• Time burden. CBT-t: 12–24 hours total across the course. Sound therapy: ongoing daily use (sleep onset, quiet workspaces). Lenire: 60 minutes/day for 12 weeks.
• Where to start. A primary-care or ENT referral that includes audiology and excludes red flags is the gatekeeping step. The British Tinnitus Association and American Tinnitus Association both maintain clinician registries.

alternatives

• Tinnitus retraining therapy (TRT) — Jastreboff's structured 18–24 month programme combining directive counselling and continuous low-level sound therapy. Cochrane found CBT > TRT on quality-of-life outcomes Fuller et al. 2020; TRT remains widely practised especially in Europe.
• MBCT-t / ACT — third-wave variants emphasising acceptance over symptom control. Evidence base smaller but comparable to CBT-t in head-to-head trials McKenna et al. 2017 Hesser et al. 2012.
• Bimodal neuromodulation — adds direct neural-plasticity-driving stimulation; FDA-approved 2023.
• Repetitive transcranial magnetic stimulation (rTMS) targeting auditory cortex — small effect sizes, inconsistent replication; not recommended in current guidelines except in research/specialist settings Tunkel et al. 2014.
• Cochlear implantation — recommended for tinnitus patients who already meet hearing-loss criteria for the implant; tinnitus reduction is a common secondary benefit Cima et al. 2019.
• Antidepressants — only when comorbid depression warrants treatment in its own right; not a tinnitus treatment.

failure-modes

• Doomscrolling tinnitus forums. Subgroup of patients with severe distress cycles through forum posts ("tinnitus drove me to suicide") that amplify catastrophic interpretation and reinforce the limbic-conditioning loop the treatment is trying to undo. Cessation of forum use is a common CBT-t homework item.
• Continued unprotected noise exposure. Concerts, power tools, headphones at high volume cause acute spikes and may worsen the underlying cochlear damage.
• Silence-seeking. Anechoic environments, quiet bedrooms, ear-plugging in normal-volume rooms — all increase relative tinnitus contrast and slow habituation.
• Loudness-monitoring. Patients who check their tinnitus loudness several times daily ("is it louder today?") reinforce attentional binding. Habituation requires deliberate dis-attention.
• Premature termination. CBT-t completion rates ~70–80%; dropouts cluster early when patients expect loudness reduction.
• Single-modality monotherapy. Hearing aids alone for a patient with major catastrophic-thought distress underperforms a combined audiological-plus-psychological pathway Cima et al. 2019.

The credibility range

Optimist case

Habituation-based care works. Two Cochrane reviews, a 2014 US guideline, and a 2019 European multidisciplinary guideline converge: CBT-t with moderate-certainty evidence reliably reduces tinnitus-related distress and quality-of-life impact in adults with chronic bothersome tinnitus, with rare adverse events Fuller et al. 2020 Tunkel et al. 2014 Cima et al. 2019. The mechanistic story is biologically coherent (central-gain plus limbic conditioning, dissociable from peripheral signal) and matches the clinical observation that loudness need not change for life to recover. Patients who reach habituation describe lives where the percept is detectable on attention but no longer foreground. Hearing aids resolve much of the distress for the subgroup with documented hearing loss Cima et al. 2019. Bimodal stimulation (Lenire) added a controlled-trial-supported, FDA-cleared device option as of 2023 Conlon et al. 2020. The "nothing can be done" frame is empirically wrong.

Skeptic case

The high-quality evidence is thinner than the guideline endorsements suggest. The Fuller 2020 Cochrane review judged certainty as low to moderate, with no 6- or 12-month follow-up evidence on whether CBT gains persist Fuller et al. 2020. Sample sizes per RCT are small. Sham/blinding is impossible for psychological interventions, so non-specific contact effects are confounded with the active component. The Sereda 2018 Cochrane review on sound therapy and hearing aids found no RCT with a waiting-list or placebo control Sereda et al. 2018. Effect sizes on tinnitus-related quality-of-life measures are modest in absolute terms — patients still have tinnitus and many still describe it as distressing. The bimodal-device trials lack sham control in the headline TENT-A1/A2 designs. No drug has cleared the bar. Many patients remain refractory after the full pathway. The field has been promising "habituation" for thirty years and the underlying nervous-system signal has never been successfully silenced.

Author's call

The treatments work for distress and function, replicably and across multiple independent guideline-level reviews; they do not reliably reduce the perceptual signal itself. That distinction is the entire editorial story. The article lands on the strong-evidence side for CBT-t as the spine of treatment, hearing aids when indicated, and structured sound enrichment as adjunct — and is honest that habituation is a months-to-years project producing partial outcomes for most, dramatic relief for some, and continued struggle for a minority. Pharmacotherapy and supplement-aisle remedies are not first-line and the article is direct about that. evidence: 4 (multiple guideline-backed RCT bodies, some certainty caveats); controversy: 2 (the field broadly agrees on the playbook, with active debate on devices and bimodal stim).

Stakeholder and incentive map

• Academic audiology and ENT — guideline producers (AAO-HNS, ENT-UK, Cima/Hoare European group). Generally cautious on devices, strongly behind CBT-t. Incentive: clinical research credibility.
• Hearing-aid manufacturers (GN ReSound, Phonak, Widex, Starkey, Oticon) — built combination devices with sound-generator features; bundle marketing around tinnitus relief. Incentive: commercial.
• Neuromod Devices (Lenire) and competitors — single product, FDA-cleared 2023; aggressive clinical-trial publishing pipeline (TENT-A1/2/3). Real-world-evidence retrospective from Alaska Hearing & Tinnitus Center reports 91.5% responder rate (selection-biased single-site). Incentive: commercial; trial designs increasingly include controls.
• Tinnitus charities (British Tinnitus Association, American Tinnitus Association, Tinnitus Hub) — patient education, clinician registries. Incentive: patient advocacy; sometimes industry-funded.
• Supplement industry (Lipo-Flavonoid in the US, ginkgo biloba globally) — heavily marketed despite guideline negative recommendations. Incentive: commercial.
• Tinnitus forums / online communities (Reddit r/tinnitus, Tinnitus Talk, Whisper) — high engagement, mixed signal: useful early-stage normalisation and treatment information; severe-distress subgroup amplifies catastrophic framing.
• US Department of Veterans Affairs — major payer for service-connected tinnitus disability claims; has its own Progressive Tinnitus Management (PTM) protocol, a stepped-care CBT-t variant. Incentive: cost-containment plus large patient population.

Population variability

• Age: Prevalence rises with age, plateauing around 60+; tracks age-related hearing loss Jarach et al. 2022.
• Sex: Jarach et al. 2022 reported no significant sex differences in pooled prevalence Jarach et al. 2022. Some cohorts find higher male prevalence reflecting occupational noise exposure.
• Hearing-loss status: The bulk of chronic tinnitus patients have measurable hearing loss, often high-frequency. About 20% of patients presenting to tinnitus clinics have audiometrically normal hearing — these patients may have hidden cochlear synaptopathy or somatosensory drivers.
• Noise-exposed populations: Military veterans, musicians, construction workers, factory workers — overrepresented. Tinnitus is the leading service-connected disability among US veterans.
• Comorbid depression/anxiety: Treatment response is reduced when these are unaddressed; combined psychological pathway is better than tinnitus-only pathway.
• Severity skew: Most people with tinnitus (~80%) are not bothered enough to seek care; the catalogue's reader is the bothered subset.
• Acute vs chronic: Tinnitus <3 months may remit spontaneously; the chronic management programme applies to ≥6-month duration.

Knowledge gaps

• Long-term durability of CBT-t. Cochrane found no evidence at 6 or 12 months post-treatment Fuller et al. 2020. Whether habituation gains persist or require booster sessions is unsettled.
• Sham-controlled sound therapy and device trials. No included RCT in the Sereda 2018 Cochrane review used a placebo or waiting-list comparator; the field cannot quantify how much hearing-aid/sound-generator benefit is non-specific Sereda et al. 2018.
• Predictors of response. The 20–30% of patients who do not respond to first-line CBT-t are poorly characterised in advance; biomarkers (e.g., specific cortical-network signatures) remain research-stage.
• Pharmacological pipeline. Several molecules in trial (gaboxadol/OTO-313 for sodium-channel modulation, AM-101 NMDA antagonist, gene therapy for sensory hair-cell regeneration) — none with reliable efficacy as of mid-2026.
• Cochlear synaptopathy ("hidden hearing loss") as a tinnitus driver in audiometrically normal patients — established in animal models, indirect human evidence; treatment implications unclear.
• What evidence would change the call. A well-powered sham-controlled CBT-t trial showing no benefit beyond contact would weaken the recommendation. A drug that demonstrably and durably reduces psychoacoustic loudness in a multi-site RCT would reshape the field's centre of gravity.

Scoping. The brief named perceived loudness, distress, sleep, concentration, CBT, sound therapy, and hearing aids — all are covered end-to-end. The entry narrows in two places worth flagging:

• Chronic subjective tinnitus only. Acute (<3 months, often spontaneously remitting), pulsatile, unilateral, somatosensory (jaw/neck-driven), and Meniere-associated tinnitus get red-flag-level mentions in contraindications but no full coverage — they have different workups and different prognoses, and trying to cover them blurs the habituation story which is the article's spine.
• Pediatric tinnitus excluded. Distinct evidence base; no psychological-therapy RCTs in children per the 2020 Cochrane scope (Fuller et al. 2020). Reader-relevant volume is much smaller.

Hard rating calls.

• sleep: 4 and mood: 4 were the dimensions most tempting to push to 5. Held at 4 because tinnitus management delivers partial relief reliably and full habituation in months-to-years — not the "new baseline" or "psychiatric-intervention-tier" transformation that 5 demands. Sleep score is anchored on the magnitude of the pre-treatment deficit (40–80% insomnia comorbidity) and the strength of post-treatment improvement, not on a clean cure.
• evidence: 4 rather than 5. The CBT evidence base is broad (28 trials in Cochrane) and guideline-backed across two continents, but Cochrane explicitly rated certainty low-to-moderate; sham-controlled device trials are absent. 5 requires the Cochrane-level "multiple large RCTs, consistent" bar, which the field doesn't yet meet for any single component.
• action: respond (not know). The reader-action question for someone without tinnitus is essentially "protect your hearing" — handled in out-of-scope via the noise-protection forward pointer. For the reader who has tinnitus, the entry is unambiguously a respond-to-symptom protocol. respond matches the dominant case.
• cadence: course (not daily or as-needed). The CBT-t treatment phase is a bounded eight-to-twelve-week course with a defined endpoint (habituation); sound-enrichment habits afterwards are maintenance at near-zero effort. The defining cadence is the course.

Bimodal stimulation (Lenire) framing. Mentioned in evidence, protocol, and alternatives but explicitly not first-line. TENT-A1/A2 trials lacked sham control; TENT-A3 is within-subject. FDA-cleared 2023. The catalogue-honest framing is "real, evidenced, expensive, second-line" — neither hype nor dismissal.

Future-link candidates. Several entries this one should cross-link to once they exist:

• noise-protection — earplugs, dB exposure limits, custom musician's plugs. Adjacent and primary-prevention.
• hearing-loss / age-related-hearing-loss — the upstream injury behind most chronic tinnitus.
• hearing-aids — the audiological piece of this pathway deserves its own treatment.
• cbt — generic CBT entry, since tinnitus-CBT is a specialised application.
• sleep-hygiene — referenced in out-of-scope.
• depression / anxiety — the bidirectional comorbidities. Once those exist, link bidirectionally.

Separate-entry candidates.

• Pulsatile tinnitus. Distinct workup (vascular imaging), distinct treatments (often surgical or interventional radiology). Warrants its own entry; currently a one-line red-flag in contraindications.
• Sudden sensorineural hearing loss. Time-critical emergency, steroid window, often presents with new tinnitus. Belongs in the broader hearing category as its own respond-action entry.
• Lenire / bimodal neuromodulation — if the evidence base matures and the product proliferates, could become its own device entry. For now consolidated here.

Tone calls. Stakes section anchors on the "bothered median sufferer" rather than the suicidal extreme (per article-spec §5c). The forum-doomscrolling failure mode is included despite reading slightly editorial because it's clinically real and clinicians warn about it routinely — the catalogue serves the reader better by naming it than by dancing around it.